Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.29% | 33.14% | 41.84% | 400.10% | 37.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -243.86% | -68.82% | 8.53% | -112.69% | -118.84% |
| Total Operating Expenses | 42.00% | 63.91% | 87.40% | 347.73% | 591.14% |
| Operating Income | -42.00% | -63.91% | -87.40% | -329.39% | -351.05% |
| Income Before Tax | -30.26% | -59.20% | -86.96% | -15.10% | 71.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.26% | -59.20% | -86.96% | -14.67% | 72.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.26% | -37.20% | -42.27% | 58.04% | 82.76% |
| EBIT | -42.00% | -63.91% | -87.40% | -329.39% | -351.05% |
| EBITDA | -- | 28.37% | -- | -- | -- |
| EPS Basic | 95.24% | 94.60% | 94.26% | 92.54% | 92.72% |
| Normalized Basic EPS | 31.07% | 80.26% | 85.03% | -102.38% | -103.85% |
| EPS Diluted | 95.24% | 94.60% | 94.26% | 92.54% | 92.72% |
| Normalized Diluted EPS | 31.07% | 80.26% | 85.03% | -102.38% | -103.85% |
| Average Basic Shares Outstanding | 273.79% | 417.22% | 1,143.19% | 1,665.11% | 806.58% |
| Average Diluted Shares Outstanding | 257.52% | 380.67% | 910.36% | 1,116.37% | 847.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |